Therapeutic benefit was defined as without suspicion of clinical activity and with the absence of new GCA symptoms (suspected to be related to GCA) and decreasing or stable CRP combined with decreasing daily prednisolone dose at three and six months post-initiation of JAKi. Here, CRP is linked to temporal arteritis.